VRTX - VERTEX PHARMACEUTICALS INC / MA
484.4
-2.030 -0.419%
Share volume: 21,804
Last Updated: Wed 05 Feb 2025 04:30:12 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.12%
PREVIOUS CLOSE
CHG
CHG%
$486.43
-2.03
-0.42%
Fundamental analysis
69%
Profitability
95%
Dept financing
7%
Liquidity
64%
Performance
60%
Performance
5 Days
4.46%
1 Month
19.82%
3 Months
-3.52%
6 Months
1.13%
1 Year
12.45%
2 Year
58.19%
Key data
Stock price
$484.40
DAY RANGE
$484.06 - $489.25
52 WEEK RANGE
$377.85 - $519.88
52 WEEK CHANGE
$15.08
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Reshma Kewalramani
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.
Recent news